1.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$1.33
Aprire:
$1.34
Volume 24 ore:
786.71K
Relative Volume:
0.39
Capitalizzazione di mercato:
$94.74M
Reddito:
-
Utile/perdita netta:
$-144.01M
Rapporto P/E:
-0.3342
EPS:
-4.01
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
+8.06%
1M Prestazione:
-0.74%
6M Prestazione:
-27.96%
1 anno Prestazione:
-68.62%
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
1599 INDUSTRIAL ROAD, SAN CARLOS
Confronta BMEA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
BMEA
Biomea Fusion Inc
|
1.34 | 94.04M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-28 | Iniziato | Jefferies | Buy |
| 2025-06-03 | Ripresa | Piper Sandler | Overweight |
| 2024-10-09 | Iniziato | Edward Jones | Buy |
| 2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Aggiornamento | Truist | Hold → Buy |
| 2024-08-29 | Iniziato | CapitalOne | Overweight |
| 2024-06-11 | Downgrade | Truist | Buy → Hold |
| 2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Iniziato | Truist | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-26 | Downgrade | Jefferies | Buy → Hold |
| 2023-05-12 | Iniziato | Barclays | Overweight |
| 2023-03-29 | Reiterato | Oppenheimer | Outperform |
| 2023-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2023-02-24 | Iniziato | Citigroup | Buy |
| 2022-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-12 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Jefferies | Buy |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Stop Loss: Is Biomea Fusion Inc. stock near bottom after declineDollar Strength & Advanced Swing Trade Entry Alerts - ulpravda.ru
Is Biomea Fusion Inc. stock near bottom after decline2025 Short Interest & Real-Time Price Movement Reports - ulpravda.ru
Will Biomea Fusion Inc. stock return to pre crisis levels2026 world cup usa national team round of 16 key players build up play expert forecast preview - ulpravda.ru
Biomea Fusion looks to major milestones in 2026 - Traders Union
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan - MSN
Biomea Fusion Inc. (BMEA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion explores challenges of insulin therapy - Traders Union
Can Biomea Fusion Inc. stock outperform in 2025 bull marketCEO Change & Detailed Earnings Play Strategies - Улправда
Published on: 2025-12-20 18:19:39 - Улправда
How interest rate cuts could boost Biomea Fusion Inc. stockWeekly Stock Recap & Daily Momentum Trading Reports - Улправда
Published on: 2025-12-20 15:52:57 - Улправда
Will Biomea Fusion Inc. stock split attract more investors2025 Technical Overview & Technical Entry and Exit Alerts - DonanımHaber
Published on: 2025-12-19 02:18:12 - Улправда
Aug Closing: Will Biomea Fusion Inc. stock outperform growth indexesJuly 2025 Action & Risk Controlled Swing Alerts - Улправда
Gap Down: Can Biomea Fusion Inc. stock outperform in 2025 bull market - Улправда
Biomea Fusion, Inc.(NasdaqGS: BMEA) dropped from NASDAQ Biotechnology Index - marketscreener.com
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Upcoming EventsBiomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Biomea Fusion presents COVALENT-111 study results at WCIRDC - MSN
Insider Buying: Biomea Fusion (NASDAQ:BMEA) Insider Acquires 30,000 Shares of Stock - MarketBeat
Biomea Fusion Director Rainer M Erdtmann Acquires 30,000 Shares - TradingView — Track All Markets
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Biomea F - GuruFocus
Interim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares - simplywall.st
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - The Manila Times
Biomea Fusion Highlights the Future of Menin Inhibitors and Icovamenib in Interview with Dr. Ralph DeFronzo at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion (Nasdaq: BMEA) features KOL talk on menin, icovamenib at WCIRDC 2025 - Stock Titan
Biomea Fusion : WCIRDC 2025 COVALENT 111 Week 52 final Oral Presentation - marketscreener.com
Is Biomea Fusion Inc a good long term investmentEarnings Revision Updates & High Profit Market Growth - earlytimes.in
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing - Investing.com Nigeria
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025 - ts2.tech
Biomea Fusion Showcases Durable Benefits Of Menin Inhibitor In Type-2 Diabetes - RTTNews
Biomea Fusion stock soars after durable diabetes treatment results By Investing.com - Investing.com Nigeria
Biomea Fusion stock soars after durable diabetes treatment results - Investing.com
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing By Investing.com - Investing.com South Africa
Biomea Fusion Presents Promising Results for Icovamenib in Treating Type 2 Diabetes at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Is Biomea Fusion Inc. stock a buy before product launchesEarnings Recap Report & Weekly Top Gainers Alerts - Newser
BMEA Insider Trading - Quiver Quantitative
Biomea Fusion Interim CEO Increases Stake with 100,000 Shares Purchase - TradingView
BMEA: Advancing Menin and oral GLP-1 therapies for diabetes, with phase II trials and strong financial runway - TradingView — Track All Markets
Biomea Fusion (BMEA) Stock Analysis Report | Financials & Insights - Benzinga
Biomea Fusion Director Rainer M Erdtmann Acquires 50,000 Shares - TradingView — Track All Markets
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):